- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Ninerafaxstat 200mg MR, Placebo
- Drug
- Lead sponsor
- Imbria Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 16
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
- Conditions
- Non-Obstructive Coronary Atherosclerosis
- Interventions
- Coronary computed tomography angiography (CCTA), Isovue, Nitroglycerin, Metoprolol
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 125 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
- Interventions
- Brezavvy 20Mg Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Moderate Intensity Exercise Program
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Coronary Artery Disease
- Interventions
- High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
- Drug · Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 2,476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Chest Pain, Ischemia
- Interventions
- 30 cc blood draw, Intravascular ultrasound (IVUS), Coronary pressure/flow wire testing, Coronary pressure/flow testing: Acetycholine challenge, Procedure: Coronary pressure/flow testing: Nitroglycerin challenge, Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2047
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging, Echocardiography, Mavacamten, Obstructive Cardiomyopathy, Hypertrophic
- Interventions
- Not listed
- Lead sponsor
- UltraSight
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Alzheimer Disease, Dementia, Heart Failure, Pulmonary Disease, Chronic Obstructive
- Interventions
- ACP Video Program
- Behavioral
- Lead sponsor
- Brown University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 197,692 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- Norcross, Georgia • Kennett Square, Pennsylvania
- Conditions
- Microvascular Angina
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
- Conditions
- Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
- Interventions
- myPACE+ algorithm
- Other
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Coronary Microvascular Dysfunction, Ischemic Non-Obstructive Coronary Artery Disease
- Interventions
- CardioFlux
- Device
- Lead sponsor
- Genetesis Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Cincinnati, Ohio • Cleveland, Ohio + 1 more
- Conditions
- Coronary Artery Disease
- Interventions
- Inclisiran sodium 300 mg, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
- Conditions
- Angina, Non-obstructive Coronary Artery Disease
- Interventions
- PET imaging, Coronary CT angiogram, Functional Angiography, Treadmill exercise stress study
- Radiation · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cardiovascular Disease (CVD), Heart Failure, Aortic Stenosis, Aortic Stenosis Disease, Hypertension, Hypertension (HTN), Hypertrophic Cardiomyopathy Patients, Hypertrophic Cardiomyopathy Without Obstruction, Hypertrophic Cardiomyopathy, Obstructive, Dilated Cardiomyopathy (DCM), Dilated Cardiomyopathy, Dilated Cardiomyopathy, Familial
- Interventions
- Not listed
- Lead sponsor
- Prolaio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois